Amit Etkin, Alto Neuroscience CEO (Alto via Vimeo)

A star Stan­ford pro­fes­sor leaves his lab for a start­up out to re­make psy­chi­a­try

About five years ago, Amit Etkin had a break­through.

The Stan­ford neu­rol­o­gist, a soft-spo­ken de­mi-prodi­gy who be­came a pro­fes­sor while still a res­i­dent, had been ob­sessed for a decade with how to bet­ter de­fine psy­chi­atric dis­or­ders. Drugs for de­pres­sion or bipo­lar dis­or­der didn’t work for many pa­tients with the con­di­tions, and he sus­pect­ed the rea­son was how tra­di­tion­al di­ag­noses didn’t ac­tu­al­ly get at the heart of what was go­ing on in a pa­tient’s brain.

He had shown in 2006 that some pa­tients with dif­fer­ent di­ag­noses — PTSD vs. de­pres­sion, for ex­am­ple — looked re­mark­ably sim­i­lar un­der brain imag­ing, sug­gest­ing clin­i­cians drew dis­tinc­tions in the wrong places. And in 2014, he showed that one could de­fine pa­tients by look­ing at in­di­vid­ual dis­crete be­hav­iors, such as at­ten­tion or sleep.

But the big ad­vance came in 2017, when his team demon­strat­ed it could pre­dict PTSD pa­tients’ re­sponse to ther­a­py by just look­ing at their brain­waves. Sim­i­lar pre­dic­tions, aid­ed with a bit of AI, fol­lowed for oth­er dis­or­ders.

“So those are the tools that re­al­ly got us ex­cit­ed,” Etkin told End­points News. “And then of course, the main ques­tion that you can’t an­swer in the lab is, how do you de­vel­op new ther­a­peu­tics around this?”

So Etkin left the lab, turn­ing his back on a bur­geon­ing aca­d­e­m­ic ca­reer to found and a run a start­up around his pre­dic­tive tech­nol­o­gy. The com­pa­ny, known as Al­to Neu­ro­science, an­nounced a $32 mil­lion Se­ries A Thurs­day, with plans to launch three Phase IIa tri­als for treat­ment-re­sis­tant de­pres­sion and PTSD with­in the next year and have its first da­ta by 2023.

With the launch, Al­to joins a grow­ing boom in neu­ro­science R&D, a field that much of big phar­ma aban­doned over the last decade.

Amit Etkin with a stu­dent

Click on the im­age to see the full-sized ver­sion

This resur­gence has been pred­i­cat­ed in part on new tech­nolo­gies, in­clud­ing the abil­i­ty to bet­ter di­vide and clas­si­fy pa­tients by their bi­ol­o­gy. Last week, ARCH, Am­gen and a long list of oth­er in­vestors threw $500 mil­lion be­hind Neumo­ra, a biotech that promis­es to use a host of dif­fer­ent met­rics and datasets to come up with so-called “pre­ci­sion phe­no­types” — pop­u­la­tions most like­ly to re­spond to a giv­en mol­e­cule.

Al­to will try to do some­thing sim­i­lar with Etkin’s tech­nol­o­gy. The pro­fes­sor-turned-CEO and his team have spent more than a year go­ing through 200-plus mol­e­cules that have been ap­proved or put in clin­i­cal de­vel­op­ment for psy­chi­atric dis­or­ders.

They did deep dili­gence on 21 of them, look­ing for those that had gone through Phase I for safe­ty and shown the right kind of bi­o­log­i­cal ac­tiv­i­ty. They in-li­censed 11 and plan to even­tu­al­ly push each in­to a psy­chi­atric sub-pop­u­la­tion that, ei­ther be­cause of a giv­en be­hav­ior or EEG pat­tern or oth­er bio­mark­er, they think will re­spond.

Etkin views the hun­dreds of failed psy­chi­a­try drugs from the last few decade as sim­ply “tools that ma­nip­u­late the brain in some use­ful way.” His goal is to find the best place to use them.

“We have all of these tools sit­ting around that we don’t quite know how to use, and we have all this bi­ol­o­gy that we’ve been flesh­ing out over these years,” he said. “This is re­al­ly how we struc­tured Al­to in terms of the strat­e­gy: to take all that knowl­edge from the past 30 years in phar­ma and biotech, and put it to work in a tar­get­ed and mean­ing­ful way.”

Etkin found his main backer in a pro­tag­o­nist of the new neu­ro boom: Chris­t­ian Anger­may­er, the Ger­man bil­lion­aire who found­ed and large­ly fund­ed ATAI, the now-$2 bil­lion com­pa­ny try­ing to de­vel­op psy­che­delics for a panoply of psy­chi­atric dis­or­ders. His firm Ape­iron led the Se­ries A.

Chris­t­ian Anger­may­er

“Al­to is well-po­si­tioned to rev­o­lu­tion­ize the treat­ment of psy­chi­atric dis­or­ders by align­ing the right pa­tient with the right drug,” he said. “At Ape­iron, we have seen re­cent ad­vance­ments at­tempt­ing to ex­pand the toolk­it for men­tal well-be­ing but con­tin­ue to rec­og­nize the dire need to im­prove the way drugs are de­vel­oped in this space.”

The com­pa­ny is keep­ing its 11 mol­e­cules un­der wraps for now, in­clud­ing the three it plans to soon put in­to Phase IIa tri­als. Those stud­ies, Etkin said, will hope­ful­ly let Al­to prove they can de­vel­op bio­mark­ers to pre­dict the best pa­tients to re­spond, al­low­ing them to de­sign piv­otal tri­als just around that group.

It’s the be­gin­ning of what Etkin hopes will be a sea change across the field, to­ward some­thing that looks a lot clos­er to where on­col­o­gy is to­day.

“In five years, in our mind, we’ve com­plete­ly changed psy­chi­a­try, we’ve changed in­to a much more pre­cise prac­tice,” he said. “And the frus­tra­tion of tri­al and er­ror for both pa­tients and clin­i­cians is — if not gone — is cer­tain­ly on the way to get­ting there.”

2023 Spot­light on the Fu­ture of Drug De­vel­op­ment for Small and Mid-Sized Biotechs

In the context of today’s global economic environment, there is an increasing need to work smarter, faster and leaner across all facets of the life sciences industry.  This is particularly true for small and mid-sized biotech companies, many of which are facing declining valuations and competing for increasingly limited funding to propel their science forward.  It is important to recognize that within this framework, many of these smaller companies already find themselves resource-challenged to design and manage clinical studies themselves because they don’t have large teams or in-house experts in navigating the various aspects of the drug development journey. This can be particularly challenging for the most complex and difficult to treat diseases where no previous pathway exists and patients are urgently awaiting breakthroughs.

Rick Modi, Affinia Therapeutics CEO

Ver­tex-part­nered gene ther­a­py biotech Affinia scraps IPO plans

Affinia Therapeutics has ditched its plans to go public in a relatively closed-door market that has not favored Nasdaq debuts for the drug development industry most of this year. A pandemic surge in 2020 and 2021 opened the doors for many preclinical startups, which caught Affinia’s attention and gave the gene therapy biotech confidence in the beginning days of 2022 to send in its S-1.

But on Friday, Affinia threw in the S-1 towel and concluded now is not the time to step onto Wall Street. The biotech has put out few public announcements since the spring of this year. Endpoints News picked the startup as one of its 11 biotechs to watch last year.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 154,000+ biopharma pros reading Endpoints daily — and it's free.

Albert Bourla, Pfizer CEO (Efren Landaos/Sipa USA/Sipa via AP Images)

Pfiz­er makes an­oth­er bil­lion-dol­lar in­vest­ment in Eu­rope and ex­pands again in Michi­gan

Pfizer is continuing its run of manufacturing site expansions with two new large investments in the US and Europe.

The New York-based pharma giant’s site in Kalamazoo, MI, has seen a lot of attention over the past year. As a major piece of the manufacturing network for Covid-19 vaccines and antivirals, Pfizer is gearing up to place more money into the site. Pfizer announced it will place $750 million into the facility, mainly to establish “modular aseptic processing” (MAP) production and create around 300 jobs at the site.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 154,000+ biopharma pros reading Endpoints daily — and it's free.

Up­dat­ed: FDA re­mains silent on or­phan drug ex­clu­siv­i­ty af­ter last year's court loss

Since losing a controversial court case over orphan drug exclusivity last year, the FDA’s Office of Orphan Products Development has remained entirely silent on orphan exclusivity for any product approved since last November, leaving many sponsors in limbo on what to expect.

That silence means that for more than 70 orphan-designated indications for more than 60 products, OOPD has issued no public determination on the seven-year orphan exclusivity in the Orange Book, and no new listings of orphan exclusivity appear in OOPD’s searchable database, as highlighted recently by George O’Brien, a partner in Mayer Brown’s Washington, DC office.

Yuling Li, Innoforce CEO

In­no­force opens new man­u­fac­tur­ing site in Chi­na

Innoforce is off to the races at its new site in the city of Hangzhou, China.

The Chinese CDMO announced last week that it has started manufacturing at the new facility, which was built to offer process development and manufacturing operations for RNA, plasmid DNA, viral vectors and other cell therapeutics. It will also serve as Innoforce’s corporate HQ.

The company said it’s investing more than $200 million in the 550,000-square-foot manufacturing base for advanced therapies. The GMP manufacturing facility features space for producing plasmids with three 30-liter bioreactors. For viral vector manufacturing, Innoforce also has 200- and 500-liter bioreactors at its disposal, along with eight suites to make cell therapies. The site also includes several labs and warehouse spaces.

Vas Narasimhan, Novartis CEO (Thibault Camus/AP Images, Pool)

No­var­tis bol­sters Plu­vic­to's case in prostate can­cer with PhI­II re­sults

The prognosis is poor for metastatic castration-resistant prostate cancer (mCRPC) patients. Novartis wants to change that by making its recently approved Pluvicto available to patients earlier in their course of treatment.

The Swiss pharma giant unveiled Phase III results Monday suggesting that Pluvicto was able to halt disease progression in certain prostate cancer patients when administered after androgen-receptor pathway inhibitor (ARPI) therapy, but without prior taxane-based chemotherapy. The drug is currently approved for patients after they’ve received both ARPI and chemo.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 154,000+ biopharma pros reading Endpoints daily — and it's free.

Pfiz­er-backed Me­di­ar Ther­a­peu­tics ropes in an­oth­er Big Phar­ma in­vestor

A biotech centered on treating fibrosis — born out of Mass General and Brigham and Women’s Hospital — has received a financial boost.

According to an SEC filing, the company has raised $31,761,186 in its latest funding round, which includes 17 investors. The filing lists six names attached to the company, including Meredith Fisher, a partner at Mass General Brigham Ventures and Mediar’s acting CEO.

Af­ter M&A fell through, Ther­a­peu­tic­sMD sells hor­mone ther­a­py, con­tra­cep­tive ring for $140M cash plus roy­al­ties

TherapeuticsMD, a women’s health company whose one-time billion-dollar valuation seems a distant memory as its blockbuster aspirations petered out, is finally cashing out.

Australia’s Mayne Pharma is paying $140 million upfront to license essentially TherapeuticsMD’s whole portfolio, including two prescription drugs that treat conditions relating to menopause, a contraceptive vaginal ring as well as its prescription prenatal vitamin brands.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 154,000+ biopharma pros reading Endpoints daily — and it's free.

FDA grants or­phan drug des­ig­na­tion to Al­ger­non's ifen­prodil, while ex­clu­siv­i­ty re­mains un­clear

As the FDA remains silent on orphan drug exclusivity in the wake of a controversial court case, the agency continues to hand out new designations. The latest: Algernon Pharmaceuticals’ experimental lung disease drug ifenprodil.

The Vancouver-based company announced on Monday that ifenprodil received orphan designation in idiopathic pulmonary fibrosis (IPF), a chronic lung condition that results in scarring of the lungs.  Most IPF patients suffer with a dry cough, and breathing can become difficult.